The interim Phase III success of CDK4/6 inhibitor Verzenio as early breast cancer adjuvant gives Lilly a clear shot at a large indication where Pfizer's CDK4/6 inhibitor Ibrance has failed $LLY $NVS $PFE https://t.co/sF6AD7aYVy